Fulfilling a promise it made to industry this spring, the US Food and Drug Administration this week released for public comment its much-anticipated draft guidance on the submission of certain pharmacogenomics data.

The draft, which the FDA’s Center for Drug Evaluation and Research originally said would be ready for public comment over the summer, is designed to generally instruct industry about when and how pharmacogenomics data should be submitted with certain new drug applications, investigational new drug applications, and biological license applications.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Polygamy amplified a rare genetic disease in area near Arizona-Utah border, BBC Future reports.

Genetic ancestry testing led one woman to learn that her father and another baby boy had been switched at birth, the Washington Post reports.

Simple de-identification methods can protect information in a database from attackers, a new study suggests.

In Science this week: approach to visualize chromatin structure in nuclei, and more.